John on for Serge Belanger's questions to Cytokinetics Inc (CYTK) leadership • Q2 2025
Question
An analyst on for Serge Belanger at Needham and Company asked how enrollment for the omecamtiv COMET trial is tracking against internal expectations.
Answer
Stuart Kupfer, SVP & Chief Medical Officer, confirmed that enrollment for the COMET-HF trial is on track to be completed by the end of 2026. President and CEO Robert Blum added that momentum is strong, partly because the trial is not competing with many others for this specific, severe patient population.